NasdaqGM:SUPN

Stock Analysis Report

Executive Summary

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

Snowflake

Fundamentals

Good value with adequate balance sheet.


Similar Companies

Share Price & News

How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.6%

NasdaqGM:SUPN

2.3%

US Pharmaceuticals

2.9%

US Market


1 Year Return

-38.8%

NasdaqGM:SUPN

-5.8%

US Pharmaceuticals

0.2%

US Market

SUPN underperformed the Pharmaceuticals industry which returned -6.8% over the past year.

SUPN underperformed the Market in United States of America which returned -0.7% over the past year.


Share holder returns

SUPNIndustryMarket
7 Day1.6%2.3%2.9%
30 Day-14.5%-1.0%-2.3%
90 Day-18.4%-3.6%3.1%
1 Year-38.8%-38.8%-3.5%-5.8%2.4%0.2%
3 Year28.5%28.5%11.3%3.7%41.7%32.4%
5 Year211.4%211.4%23.3%10.3%55.1%37.9%

Price Volatility Vs. Market

How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Supernus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

36%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Supernus Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Supernus Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Supernus Pharmaceuticals is good value based on earnings compared to the US Pharmaceuticals industry average.

Supernus Pharmaceuticals is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Supernus Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

Supernus Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Supernus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

12.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Supernus Pharmaceuticals's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).

Supernus Pharmaceuticals's earnings are expected to grow by 12% yearly, however this is not considered high growth (20% yearly).

Supernus Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Supernus Pharmaceuticals's earnings growth is positive but not above the United States of America market average.

Supernus Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Supernus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Supernus Pharmaceuticals performed over the past 5 years?

50.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Supernus Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.

Supernus Pharmaceuticals's 1-year earnings growth is less than its 5-year average (21.1% vs 50.4%)

Supernus Pharmaceuticals's earnings growth has not exceeded the US Pharmaceuticals industry average in the past year (21.1% vs 24.3%).


Return on Equity

Supernus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Supernus Pharmaceuticals used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Supernus Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Supernus Pharmaceuticals's financial position?


Financial Position Analysis

Supernus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Supernus Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Supernus Pharmaceuticals's level of debt (64.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (84.9% vs 64.5% today).

Debt is well covered by operating cash flow (46.6%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 45x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.2x debt.


Next Steps

Dividend

What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Supernus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Supernus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Supernus Pharmaceuticals has not reported any payouts.

Unable to verify if Supernus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Supernus Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Supernus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

7.1yrs

Average management tenure


CEO

Jack Khattar (58yo)

14.6yrs

Tenure

US$7,215,836

Compensation

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has been its Chief Executive Officer, President, Secretary and Director since 2005. From 1999 to  ...


CEO Compensation Analysis

Jack's remuneration is higher than average for companies of similar size in United States of America.

Jack's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.


Management Age and Tenure

7.1yrs

Average Tenure

64yo

Average Age

The average tenure for the Supernus Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.5yrs

Average Tenure

66.5yo

Average Age

The tenure for the Supernus Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jack Khattar (58yo)

    Founder

    • Tenure: 14.6yrs
    • Compensation: US$7.22m
  • Gregory Patrick (68yo)

    Senior VP & CFO

    • Tenure: 7.8yrs
    • Compensation: US$1.24m
  • Padmanabh Bhatt (62yo)

    Chief Scientific Officer & Senior VP of Intellectual Property

    • Tenure: 7.4yrs
    • Compensation: US$1.23m
  • Tami Martin (64yo)

    Senior Vice President of Regulatory Affairs

    • Tenure: 0.0yrs
  • Stefan K. Schwabe (67yo)

    Chief Medical Officer and Executive VP of Research & Development

    • Tenure: 7.1yrs
    • Compensation: US$1.28m
  • Todd Horich

    Vice President of Marketing

    • Tenure: 4.6yrs
  • Taylor Raiford

    Vice President of Sales

    • Tenure: 4.6yrs
  • Bryan Roecklein

    Vice President of Corporate Development

    • Tenure: 4.1yrs

Board Members

  • Chuck Newhall (74yo)

    Chairman of the Board

    • Tenure: 3.0yrs
    • Compensation: US$298.13k
  • John Siebert (79yo)

    Director

    • Tenure: 8.6yrs
    • Compensation: US$277.13k
  • Jack Khattar (58yo)

    Founder

    • Tenure: 14.6yrs
    • Compensation: US$7.22m
  • Georges Gemayel (59yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$267.13k
  • Carrolee Barlow (55yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$365.09k
  • Frederick Hudson (74yo)

    Director

    • Tenure: 9.6yrs
    • Compensation: US$282.13k

Company Information

Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Supernus Pharmaceuticals, Inc.
  • Ticker: SUPN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.439b
  • Shares outstanding: 52.45m
  • Website: https://www.supernus.com

Number of Employees


Location

  • Supernus Pharmaceuticals, Inc.
  • 1550 East Gude Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SUPNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2012
S49DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2012
0LB2LSE (London Stock Exchange)YesCommon StockGBUSDMay 2012

Biography

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers O ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 00:29
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.